Cruces University Hospital, Basque Country University UPV/EHU, Biocruces Bizkaia Health Research Institute, Bizkaia, Spain.
Clínic Hospital of Barcelona, Clínic Institute of Ophthalmology, University of Barcelona, Biomedical Research Institute August Pi I Sunyer (IDIBAPS), Barcelona, Spain.
Ocul Immunol Inflamm. 2023 Feb;31(2):286-291. doi: 10.1080/09273948.2022.2026413. Epub 2022 Feb 24.
To assess the clinical features, management and prognosis of patients diagnosed with tubulointerstitial nephritis and uveitis (TINU) syndrome in Spain and Portugal.
Retrospective multicenter study, which included all patients diagnosed with TINU syndrome managed in 15 uveitis referral centers from Spain and Portugal.
Forty-eight subjects with a mean age at diagnosis of 25.0 [14.8; 49.5] years were included. Both eyes were affected in 43 patients (89.6%). The visual outcome was favorable, but immunosuppressive systemic therapy (IST) was needed in 26 (54.16%) due to relapses. Renal function normalized in 35 patients (72.9%). HLA-DQB1*05 was the most common genetic typing (57.1%). The mean follow-up time was 22.5 [11.0; 48.0] months.
Both visual and renal outcomes were favorable, although IST was frequently used. TINU is under- diagnosed, so further prospective studies would provide more knowledge about its recognition and management.
TINU Syndrome is underdiagnosed because ocular and renal disease are asynchronous. Outcomes are favorable so it has to be highly suspected in cases of bilateral anterior uveitis. According to literature and our experience, systemic immunosuppressive therapy is often required because of ocular relapses.This study adds to the previous knowledge that HLA-DQB1*05 could be an important HLA type amongst the TINU Syndrome Iberian population. HLA typing should be assessed in these patients in order to describe its phenotype-genotype relationship better. A considerable number of patients in our series were diagnosed in their sixties, so TINU Syndrome should also be suspected in elderly patients.
评估在西班牙和葡萄牙被诊断为肾小管间质性肾炎和葡萄膜炎(TINU)综合征的患者的临床特征、治疗方法和预后。
这是一项回顾性多中心研究,纳入了在西班牙和葡萄牙的 15 个葡萄膜炎转诊中心接受 TINU 综合征治疗的所有患者。
共纳入 48 例平均年龄为 25.0[14.8;49.5]岁的患者。43 例(89.6%)双眼受累。尽管预后良好,但由于复发,26 例(54.16%)需要免疫抑制全身治疗(IST)。35 例(72.9%)肾功能恢复正常。最常见的遗传类型是 HLA-DQB1*05(57.1%)。平均随访时间为 22.5[11.0;48.0]个月。
尽管经常使用 IST,但视力和肾脏结局都较好。TINU 诊断不足,因此进一步的前瞻性研究将提供更多关于其识别和管理的知识。
TINU 综合征诊断不足,因为眼部和肾脏疾病不同步。由于眼部复发,通常需要全身免疫抑制治疗,因此对于双侧前葡萄膜炎患者应高度怀疑。根据文献和我们的经验,通常需要全身免疫抑制治疗,因为眼部复发。本研究增加了之前的知识,即 HLA-DQB1*05 可能是 TINU 综合征伊比利亚人群中的一个重要 HLA 类型。为了更好地描述其表型-基因型关系,应在这些患者中评估 HLA 分型。我们的系列中有相当数量的患者在六十多岁时被诊断出来,因此也应怀疑老年患者患有 TINU 综合征。